Salute e Benessere

Total number of shares and voting rights in Zealand Pharma at January 31, 2024

Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the...
Nasdaq GlobeNewswire
31/01/2024

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without…

BBS-Bioactive Bone Substitutes Plc, Company announcement, 31 January 2024 at 6.00 p.m. EETBBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself BBS-Bioactive Bone Substitutes Plc's Board of Directors has decided on 31 January 2023 to issue 1,000,000 shares without consideration to the company itself, for potential loan conversions as well as for other possible purposes, in accordance with authorisation from the Extraordinary...
Nasdaq GlobeNewswire
31/01/2024

Synergy Spine Solutions Announces $30M Financing

Synergy remains at the forefront of addressing the critical need for innovative solutions in cervical disc replacement. Enrollment for the Synergy Disc® 1-level IDE trial was recently completed in June 2023. Synergy remains at the forefront of addressing the critical need for innovative solutions in cervical disc replacement. Enrollment for the Synergy Disc® 1-level IDE trial was recently completed inJune 2023. The 2-Level trial will evaluate the safety and effectiveness of the Synergy...
PR Newswire
31/01/2024

Carrier Screening Market Worth $5.4 Billion | MarketsandMarkets™

Browse in-depth TOC on "Carrier Screening Market" Browse in-depth TOC on "Carrier Screening Market" 206 - Tables 48 - Figures 232 - Pages Carrier Screening Market Scope: Predesigned Panel Testing in Expanded Carrier Screening type segment to witness the highest shares during the forecast period." Based on the type, the global Carrier Screening Market is segmented into Expanded Carrier Screening (Customized Panel Testing, Predesigned Panel Testing)., and Targeted...
PR Newswire
31/01/2024

Global Surgical Robots Market to Record Strong Growth at 17.46% CAGR, Accounting…

Get a Sample PDF of the Report:https://www.kingsresearch.com/request-sample/surgical-robots-market-325 Get a Sample PDF of the Report:https://www.kingsresearch.com/request-sample/surgical-robots-market-325 Trending Now: Apollo Unveils da Vinci Xi: Elevating Precision and Patient Outcomes in Complex Surgeries InApril 2023, Apollo introduced the da Vinci Xi robotic surgical system, a cutting-edge technology designed for complex surgeries. Boasting precision and control, this...
PR Newswire
31/01/2024

Spielwarenmesse: outstanding product innovations receive ToyAward

Category Baby & Infant (0-3 years) Category Baby & Infant (0-3 years) Basic Building Blocks – Multicolored, Haba Building blocks are the epitome of a long-established play concept that fascinates children from a very young age. With these Basic Building Blocks – Multicolored, they get to know the basic geometric shapes through the medium of play and train their motor, sensory and creative skills. Moreover, the robust building blocks can be easily combined with other products from...
PR Newswire
31/01/2024

Coloplast launches Biatain® Silicone Fit for pressure injury prevention and…

The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. “We are now introducing new innovation to the US market, aiming to grow our presence within the foam dressings segment. We have a great product in our hands, and we have invested significantly in our sales organization to reach the full potential of this launch. I am really excited to get started,” says Kimberly Ditter, Vice...
Nasdaq GlobeNewswire
31/01/2024

TriNetX Joins CERTAINTY Project to Enhance Cancer Immunotherapy

"As a research-focused company, we are committed to advancing cancer research using real-world data. With our unique, anonymous dataset and experienced team, we are strategically positioned to expedite key results for the CERTAINTY research program, making a swift and impactful contribution to the field," said Guillaume Azarias, Senior Data Scientist at TriNetX Oncology. "As a research-focused company, we are committed to advancing cancer research using real-world data. With our…
PR Newswire
31/01/2024

New Philips Mini TEE ultrasound transducer helps improve cardiac care for more…

Latest innovation has the potential to reduce anesthesia during minimally invasive procedures [1] As a pioneer and leading innovator in cardiac ultrasound, Philips has developed the smaller X11- 4t Mini 3D TEE transducer to serve more patients with this valuable imaging tool, from pediatric patients to older adults and everyone in between Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its latest TEE...
Nasdaq GlobeNewswire
31/01/2024

Total number of voting rights and capital on January 31, 2024

Total number of voting rights and capital on January 31, 2024January 31, 2024Company announcement No. 05 Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292...
Nasdaq GlobeNewswire
31/01/2024

Neurimmune to regain global rights to brain amyloid depleter for the treatment…

Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered Neurimmune licensed its antibody aducanumab for the treatment and prevention of Alzheimer's disease to Biogen in 2007 and will hold global rights to the program following Biogen's termination of the collaboration and license agreement. In addition to rights to an extensive IP portfolio relating to the antibody, Neurimmune is obtaining a detailed clinical data package, GMP supplies and...
Nasdaq GlobeNewswire
31/01/2024

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 31 January 2024– Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022. The reports are available at the SEC's website, www.sec.gov, as well as onnovonordisk.com. Shareholders may receive a hard copy of Novo Nordisk's completed audited financial statements free of charge upon request to...
Nasdaq GlobeNewswire
31/01/2024

Nuclear Medicine Market Size to Grow USD 10260 Million by 2029 at a CAGR of 7.4%…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-3I2814/Global_Nuclear_Medicine_Market Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-3I2814/Global_Nuclear_Medicine_Market Major Factors Driving the Growth of Nuclear Medicine Market Numerous important elements are driving the significant rise of the nuclear medicine market. The need for accurate diagnosis and treatment options has increased due to the rising...
PR Newswire
31/01/2024

Biogen to Realign Resources for Alzheimer's Disease Franchise

Company to reprioritize resources allocated to ADUHELM ®(aducanumab-avwa) to advance LEQEMBI ®(lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer's disease franchise to address patient needs CAMBRIDGE, Mass., Jan.31, 2024(GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer's disease (AD), a strategic therapeutic area expected to drive near and long-term growth...
Nasdaq GlobeNewswire
31/01/2024

IM Cannabis Receives 180 Calendar Day Extension from the Nasdaq Stock Market to…

The Company will continue to monitor the closing bid price of its common stock and plans to pursue available options to regain compliance with the Bid Price Rule, including potentially pursuing a reverse stock split. If the Company authorizes a reverse stock split, it will plan to effectuate the split no later than ten business days prior to the end of the extension in order to regain compliance. The Company will continue to monitor the closing bid price of its common stock and plans to…
PR Newswire
31/01/2024

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the…

LONDON and NEW YORK, Jan.31, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, announces that following its positive safety and efficacy results in its Phase 2 trial of OK-101, distinguished ophthalmologists, Victor Perez,...
Nasdaq GlobeNewswire
31/01/2024

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation…

Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer1 Fast Track designation can facilitate the development and expedite the regulatory review of BNT325/DB-1305 Ovarian cancer is the fourth most common gynecological tumor type2 with over 300,000 cases diagnosed globally each year3; over 90% of ovarian tumors arise from...
Nasdaq GlobeNewswire
31/01/2024

Zymeworks Announces Participation in Upcoming Investor Conferences

Guggenheim Healthcare Talks 6 thAnnual Biotechnology Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on February 8 that 2:30 pm Eastern Time (ET) in New York, NY.Oppenheimer 34 thAnnual Healthcare Life Sciences Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on February 13 that 9:20 am ET.Citi's 2024 Virtual Oncology Leadership Summit: Zymeworks' management will participate in a fireside...
Nasdaq GlobeNewswire
31/01/2024

Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and…

Norma brings over 20 years of broad experience and deep expertise in oncology, diagnostics and reimbursement. She also brings extensive experience of leading teams in planning and executing thought leader engagement, evidence-generation, and scientific communications strategies. Norma most recently held the position of VP of Medical Affairs at Aadi Biosciences where she developed and executed the medical strategy and plan. She has also held a similar position at Kaleido Biosciences, with prior…
PR Newswire
31/01/2024

Half-year report

DXS INTERNATIONAL PLC(AQSE: DXSP)HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2023. Financial highlights:Revenue increased by 2.5% to £1,693,910 (2022 - £1,652,467).Core recurring revenue model remains resilient.(Loss)/Profit after tax of (£121,562) compared to £27,656 in 2022, a decrease of...
Nasdaq GlobeNewswire
31/01/2024

WuXi Biologics Successfully Completes First 16,000L Manufacturing Run in Ireland

The manufacturing run reached 16,000-liter scale by combining four 4,000-liter single-use bioreactors. This pioneering paradigm marks not only the first successful manufacturing run for the MFG7 facility, but also the largest manufacturing scale for WuXi Biologics to date. The Cost of Goods (COGS) from this run is comparable to that of a 16,000-liter traditional stainless-steel bioreactor, reinforcing the comparable cost seen in over 100 runs at 12,000-liter scale single-use bioreactors…
PR Newswire
31/01/2024

BioSenic provides support to forthcoming European conference on…

Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST –BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD).GvHD can result from transplanting bone marrow or...
Nasdaq GlobeNewswire
31/01/2024

IGIN: the first innovative device for automatic glove fitting, is now launching…

Disposable gloves are essential in many sectors. IGIN gloves are suitable for any industry where sterile gloves are used such as food service and retail. Traditional methods of wearing gloves further exacerbate these problems, often leading to cross-contamination and a higher risk of infection. Disposable gloves are essential in many sectors. IGIN gloves are suitable for any industry where sterile gloves are used such as food service and retail. Traditional methods of wearing gloves further...
PR Newswire
31/01/2024

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN…

With 21st.BIO's platform, customers have access to world-leading industrial production strains, fermentation processes, as well as support with scale-up, tech transfers to contract manufacturers, and regulatory approvals to get to market at speed and with lower costs. 21st.BIO continuously optimizes the strains and processes, ensuring customers are always ahead of the market. With 21st.BIO's platform, customers have access to world-leading industrial production strains, fermentation…
PR Newswire
31/01/2024
Altri  Comunicati